Sarcopedia

MalignantSoft tissue

Alveolar Soft Part Sarcoma

Synonyms: ASPS

Deceptively slow-growing despite high-grade histology

Quick Facts

Behaviour

Malignant

Category

Soft tissue

Grade

High

Synonyms

ASPS

Category

Soft tissue

Behaviour

Malignant

Grade

High

Gender

Female

Tissue of Origin

Unknown (possible muscle or neural crest origin)

Epidemiology

  • Rare, 0.5–1% of soft tissue sarcomas
  • Peak incidence in adolescents and young adults (15–35 years), but wide age range of presentation
  • Slow-growing despite high-grade histology

Clinical Features

  • Painless slow-growing deep soft tissue mass
  • Up to 70% have metastases at presentation
  • Often large at presentation due to indolent course
  • Pulsatile mass or prominent vessels may be evident
  • Brain metastases can present as neurological symptoms

Location

  • Deep soft tissues of the extremities (thigh and buttock) most common in adults
  • Head and neck (tongue, orbit) more common in children
  • Rarely trunk or retroperitoneum

Imaging

  • Well-defined hypervascular mass on CT and MRI
  • Prominent internal and peripheral flow voids on MRI (flow vessels)
  • Can mimic AV malformation on angiography

Pathology

  • Large polygonal cells with an abundant eosinophilic cytoplasm
  • PAS-positive diastase-resistant crystals (pathognomonic)
  • Nests of tumor cells with surrounding vascular channels

Genetics

  • ASPSCR1-TFE3 gene fusion (der(17)t(X;17)(p11;q25))
  • Unbalanced translocation always present
  • TFE3 FISH/IHC confirmatory

Treatment

  • Wide surgical resection of primary lesion
  • Excision of brain and lung mets may prolong survival
  • Radiotherapy considered in unresectable lesions or with positive margins
  • VEGFR inhibitors show strong response in metastatic disease
  • Multiple immunotherapy agents being trialed
  • Cytotoxic drugs have limited efficacy

Prognosis

  • Indolent course but high rate of metastasis (lungs, bone, brain)
  • 5-year survival 47-68%, very good in local disease (73-100%) and 20-60% in those with metastases.
  • Late metastasis common (>10 years after resection)
  • Brain metastases associated with very poor outcome

Key Points

  • Deceptively slow-growing despite high-grade histology
  • Metastatic propensity (43% at presentation)
  • TFE3 rearrangement is diagnostic
  • Long-term surveillance required - late metastasis well recognised

Workup - Blood Tests

FBC, U&E, LFTs - baseline

Workup - Local Imaging

MRI with contrast of primary site

Workup - Biopsy

Core needle biopsy

Workup - Staging

  • CT chest/abdomen/pelvis
  • MRI brain - brain metastases common
  • Whole body PET-CT per LSESN guidelines

Workup - Other

MDT review with sarcoma specialist centre

Follow-up Summary

  1. Soft Tissue Tumours - Localised Extremity - Intermediate and High Grade

    Year 10+

    Continue surveillance - late metastasis (lung, bone, brain) well recognised >10 years post-resection

Medical disclaimer

The content on Sarcopedia is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis or treatment. Always consult with a qualified physician regarding any health concerns or before starting any new treatment. Reliance on any information provided on this site is solely at your own risk.